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Abstract
Background:  Beta-thalassemia is a common autosomal recessive hereditary disease in the
Meditertanean, Asia and African areas. Over 600 mutations have been described in the beta-globin
(HBB), of which more than 200 are associated with a beta-thalassemia phenotype.
Results:  We used two highly-specific mutation screening methods, mismatch-specific
endonuclease and denaturing high-performance liquid chromatography, to identify mutations in the
HBB gene. The sensitivity and specificity of these two methods were compared. We successfully
distinguished mutations in the HBB gene by the mismatch-specific endonuclease method without
need for further assay. This technique had 100% sensitivity and specificity for the study sample.
Conclusion: Compared to the DHPLC approach, the mismatch-specific endonuclease method
allows mutational screening of a large number of samples because of its speed, sensitivity and
adaptability to semi-automated systems. These findings demonstrate the feasibility of using the
mismatch-specific endonuclease method as a tool for mutation screening.
Background
Beta-thalassemia is one of the most common genetic dis-
eases in the world. It is an autosomal recessive inherited
disease resulting from point mutations, small insertions,
or deletions in the beta-globin (HBB) gene [1]. Over 600
mutations have been described in the HBB gene, of which
more than 200 are associated with a beta-thalassemia
phenotype [2,3]. The wide diversity of mutations in the
HBB  genes makes mutation screening time-consuming
and expensive. In the Southeast Asian population, the
common beta-thalassemia mutations include c.-78 A>G,
c.2 T>A, c.52 A>T, c.84_85 insC, c.125_128 delTCTT,
c.130 G>T, c.216_217 insA, and c.316-197 C>T [4].
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A wide variety of methods for genotyping the HBB gene
have been developed using different detection techniques
based on different principles [5], including allele-specific
oligonucleotide hybridization (ASO) [6], amplification
refractory mutation system (ARMS) [7], allele-specific
PCR [8], reverse dot blot [9], restriction fragment length
polymorphism (RFLP) [10], single base extension (SBE)
[11,12], and others [13-17]. These methods, however, are
limited to the study of hotspot or known mutations. Addi-
tionally, single-strand conformation polymorphism
(SSCP) [18,19], denaturing gradient gel electrophoresis
(DGGE) [20], temporal temperature gel electrophoresis
(TTGE) [21], are efficient techniques to screen for
unknown mutations. The advantage of these methods
above is that it is inexpensive and suitable for large-scale
research applications. However, its major disadvantage is
lower detection rates. Recently, chemical cleavage of mis-
match (CCM) [22] analysis has been reported to be a
promising tool for mutation detection with advantages of
accuracy, simplicity, and cost effectiveness, but it involves
the use of toxic chemicals.
Enzymatic mismatch cleavage methods have been around
for some time and include the use of T4 endonuclease VII
[23], endonuclease V (Endo V) [24], mung bean nuclease
[25], S1 nuclease [26], and CEL I nuclease [27-29]. There
are growing numbers of publications describing the use of
mismatch-specific endonuclease in the mutation discov-
ery methods known as Tilling and Ecotilling [30-32].
In this study, we used the mismatch-specific endonuclease
method to detect disease-causing mutations in the HBB
gene. The method was modified by amplifying the PCR
products using three primers in the HBB gene labeled at 5'
ends with fluorescent dyes. The results obtained using the
mismatch-specific endonuclease method were compared
with findings using denaturing high-performance liquid
chromatography (DHPLC).
Results
Detection of HBB Mutations by the Mismatch-specific 
Endonuclease Method
Chemical cleavage of mismatch (CCM) is a highly specific
and sensitive method to induce mismatch-cleavages [33].
However, the major disadvantage of CCM is the use of
toxic chemicals during the process in the reactions or buff-
ers, which could be avoided by using enzymatic mismatch
cleavage. The celery enzyme is a member of a family of
plant endonucleases that recognizes mismatches in heter-
oduplex DNA and cleaves both strands on the 3' side of
the mismatch distortion [27]. To investigate the diagnos-
tic value of this approach, the exons of HBB genes were
amplified by PCR using primers labeled at the 5' end with
fluorescent dyes (Figure 1). We also employed a simple
method to detect mutations in HBB genes using the mis-
match-specific endonuclease cleavage and separation of
the PCR products by capillary electrophoresis. The
approach is based on mismatch-specific selective reac-
tions of mismatched DNA cleavage by endonuclease and
separation of the PCR product fragments by capillary elec-
trophoresis. This method is also adaptable to automated
capillary electrophoresis which could increase its speed,
sensitivity, and reproducibility, making it suitable for
large-scale and high-throughput mutation screening.
We detected all the DNA variants of the HBB gene includ-
ing single base substitutions and deletions of TCTT. The
different mutation sites and the expected sizes of PCR
products cleaved by mismatch-specific endonuclease are
described in Table 1. Samples of variant DNA fragments
obtained with different base pairs were analyzed using
capillary electrophoresis and the results are shown in Fig-
ure 2.
The PCR fragment amplified by the B1 and B2 primers
was 337 bp; this fragment was cut into fragments of 107
bp and 230 bp by mismatch-specific endonuclease indi-
catingthe presence of c.-78 A>G mutation (Fig. 2A). Simi-
lar to the c.-78 A>G variation, the common c.9 C>T single
nucleotide polymorphism (SNP) of the PCR fragment was
cleaved to 193 bp and 144 bp (Fig. 2C).
Table 1: Variation sites and the expected lengths of mismatch-specific endonuclease cleavage fragments for the human HBB gene
Variations Sites Nucleotide Change Amplicon Mutation Type Expected Fragment Lengths (bp)
Observation with FAM 
labeling
Observation with HEX labeling
c.-78 A>G B1B2 (337 bp) Regulatory 107 230
c.2 T>G B1B2 (337 bp) Misense 186 151
c.9 C>T B1B2 (337 bp) SNP 193 144
c.52 A>T B1B2 (337 bp) Nonsense 236 101
c.125_128 delTCTT B3B4 (287 bp) Frame shift 125 162
c.316-197 C>T Y3Y4 (423 bp) Splicing 198 225
c.316-185 T>C Y3Y4 (423 bp) SNP 210 213BMC Biotechnology 2008, 8:62 http://www.biomedcentral.com/1472-6750/8/62
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The FAM- and HEX-labeled probes had the same sensitiv-
ity and specificity and could be used for double confirma-
tion of the results. The formation of new cleavage
products indicated the presence of variation, while their
size provided some information about their location in
the entire gene (Figure 3). The two variations could be
also determined by the mismatch-specific endonuclease
method as shown in Figure 2. The 107 bp, 230 bp, 186 bp,
and 151 bp cutting by mismatch-specific endonuclease
represented the presence of compound heterozygous var-
iations (c.-78 A>G with c.2 T>A) (Fig. 2H). Similarly, the
193 bp, 144 bp, 236 bp, and 101 bp due to c.9 C>T poly-
morphism combined with the c.52 A>T variation (Fig. 2I).
The other DNA substitutions were identified by following
this principle to predict the locations of the mutation
sites. This technique could be the gold standard for the
identification of healthy carriers, while for the diagnosis
of affected patients direct sequencing probably remains
the best approach, also considering the small size of HBB
gene.
Detection of HBB mutations by DHPLC
DHPLC is a promising tool for mutations detection and
gene quantification [34-36]. Previously, we developed a
powerful and rapid PCR-DHPLC assay for detection of
HBB mutations [37]. However, DHPLC had better sensi-
tivity and specificity in the analysis of heteroduplexes in
PCR fragments shorter than 500 bp. In an attempt to
increase sensitivity, we modified and optimized the PCR
primers and DHPLC conditions for this study (Table 2),
providing a significant advantage to this technique. The
modified assay was used for identification of various gen-
otypes of the HBB gene (Figure 4) which were confirmed
by direct sequencing.
Principles of the mismatch-specific endonuclease cleavage of the heteroduplex formation using primers labeled with two differ- ent fluorescent dyes Figure 1
Principles of the mismatch-specific endonuclease cleavage of the heteroduplex formation using primers 
labeled with two different fluorescent dyes.BMC Biotechnology 2008, 8:62 http://www.biomedcentral.com/1472-6750/8/62
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HBB  genes could contain one or more mutations that
could affect the results of DHPLC. This results in complex
chromatography as shown in Figure 4, and failure to eas-
ily determine the genotype.
Discussion
Heteroduplex analysis based on DHPLC and mismatch-
specific endonuclease with capillary electrophoresis both
have the ability to detect unknown mutations. At present,
direct sequencing is the gold standard and its use with
multi-capillary electrophoresis, allows for high-through-
put automation. Direct sequencing analysis is almost
100% sensitive for the detection of point mutations, small
insertions, and deletions. The greatest advantage of
DHPLC is its high sensitivity. This method shows small
changes in peak chromatography according to differences
in hydrophoretic mobility between heteroduplex and
homoduplex DNA with high reproducibility. The main
advantage of the mismatch-specific endonuclease cleav-
age method is that it can determine the locations of muta-
tions with good sensitivity and without the use of toxic
chemicals. Nonetheless, because it uses fluorescence tech-
nology, it is more expensive to run. In the present study,
we were able to unambiguously identify all of the geno-
types in HBB variants by either of these methods with
100% sensitivity and specificity.
Capillary electrophoresis analysis of HBB genes for PCR products cleaved by mismatch-specific endonuclease from A) an individ- ual with a genotype of c.-78 A>G/WT Figure 2
Capillary electrophoresis analysis of HBB genes for PCR products cleaved by mismatch-specific endonuclease 
fromA) an individual with a genotype of c.-78 A>G/WT, B) an individual with a genotype of c.2 T>G/WT, C) an individual with a 
genotype of c.9 C>T/WT, D) an individual with a genotype of c.52 A>T/WT, E) an individual with a genotype of c.125_128 
delTCTT/WT, F) an individual with a genotype of c.316-197 C>T/WT, G) an individual with a genotype of c.316-185 T>C/
WT, H) an individual with a genotype of compound heterozygous mutation c.-78 A>G/c.2 T>G, I) an individual with a geno-
type of c.9 C>T/c.52 A>T, and J) an individual with a genotype of c.316-197 C>T/c.316-185 T>C.BMC Biotechnology 2008, 8:62 http://www.biomedcentral.com/1472-6750/8/62
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DHPLC, direct sequencing, and mismatch-specific endo-
nuclease cleavage all require PCR amplification prior to
screening. Thus, the major time factor is the machine run
time. The DHPLC method can efficiently analyze one PCR
product within 10 min. While the mismatch-specific
endonuclease method reactions used in this study
required single runs on a single capillary electrophoresis
machine, 96-capillary sequencers are available that can be
used for mismatch-specific endonuclease cleavage and
Human beta-globin gene sequence (NG_000007), primer locations and the variation sites Figure 3
Human beta-globin gene sequence (NG_000007), primer locations and the variation sites. The primers are 
labeled in boldface letters and blue font, the mutation sites are labeled in boldface letters and red font, and the polymorphism 
are marked in boldface letters and green font. The overlap sequence is labeled in pink font.
Table 2: Primers used for DHPLC and mismatch-specific endonuclease cleavage analysis of the HBB gene
Primer Name Sequence (5'-3') PCR Length (bp) Anneal Tm (°C) DHPLC Tm (°C) DHPLC %B 
Start/end
5'-Label
B1 gacaggtacggctgtcatca 337 56 61 55–64 4.5 min FAM
B2 gtctccacatgcccagtttc HEX
B3 gaaactgggcatgtggagac 287 56 61 55–64 4.5 min FAM
B4 agcttgtcacagtgcagctc HEX
Y3 gtgtacacatattgaccaaa 423 56 56 56–65 4.5 min FAM
Y4 agcacacagaccagcacgt HEXBMC Biotechnology 2008, 8:62 http://www.biomedcentral.com/1472-6750/8/62
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direct sequencing. The 96-capillary machine can process
more samples per hour than a DHPLC machine [38].
We calculated the costs of the screening at approximately
$6 per patient for two different exons using DHPLC anal-
ysis and another $14 for direct sequencing. The cost of the
mismatch-specific endonuclease e cleavage mutation
detection was calculated at about $9 per exon, thus it cost
approximately $18 per patient for two exons.
In the case where a mutation and polymorphism occur in
the same PCR amplicon, the variable polymorphism may
affect the DHPLC profile and running conditions (Fig. 4);
however, the two mutations could be determined by mis-
match-specific endonuclease because the mismatch-spe-
cific endonuclease cleavage method can accurately
identify the base variant and its location (Fig. 2). None-
theless, the mismatch-specific endonuclease cleavage
method is more time consuming and complicated
because it requires FAM- and HEX-labeled primers.
DHPLC is very simple and rapid and uses unlabeled prim-
ers. Data interpretations are easy with both the mismatch-
specific endonuclease method and DHPLC. These two
methodologies cannot detect large deletions or duplica-
tions in genotypes, however, unless multiplex PCR is
designed for DHPLC or capillary electrophoresis [39-41].
DHPLC chromatography analyses of HBB genes for PCR products Figure 4
DHPLC chromatography analyses of HBB genes for PCR products. (amplicon B1B2 for a, b, c, d, e, f ; B3B4 for g and Y3Y4 for 
h, i, j). a) an individual with a genotype of c.-78 A>G/WT, b) an individual with a genotype of c.2 T>G/WT, c) an individual with 
a genotype of c.9 C>T/WT, d) an individual with a genotype of c.52 A>T/WT, e) an individual with a compound heterozygous 
mutation c.-78 A>G/c.2 T>G, f) an individual with a genotype of c.9 C>T/c.52 A>T, g) an individual with a genotype of 
c.125_128 delTCTT/WT, h) an individual with a genotype of c.316-197 C>T/WT, i) an individual with a genotype of c.316-185 
T>C/WT, and j) an individual with a genotype of c.316-197 C>T/c.316-185 T>C.BMC Biotechnology 2008, 8:62 http://www.biomedcentral.com/1472-6750/8/62
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On the other hand, Multiplex Ligation-dependent Probe
Amplification (MLPA) [42] is more generally used to
detect large deletions causing beta-thalassemia [43].
Conclusion
The mismatch-specific endonuclease method for beta-tha-
lassemia mutations detection is merely as a model for
other (large) disease genes for which large scale, high-
throughput mutation scanning. This study demonstrated
that the mismatch-specific endonuclease method was not
only a comparatively faster procedure but was also signif-
icantly superior to DHPLC as a tool for gene mutation
identification. The method is feasible for use in high-
throughput systems due to an automated injection. This
method is thus well suited for screening and may also
reduce costs.
Methods
DNA Extraction
DNA samples were obtained from a total of 50 subjects,
including 20 carriers, 20 patients, and 10 normal individ-
uals at National Taiwan University Hospital. Genomic
DNA was collected from peripheral whole blood using the
Chemagic DNA Blood Kit (Chemagen) according to the
manufacturer's instructions. The different genotypes of
the DNA samples used in the mismatch-specific endonu-
clease study are shown in Table 1.
Polymerase Chain Reaction
PCR primers and conditions for each exon to amplify the
HBB gene were modified according to previously reported
methods [37] and are described in Table 2. The PCR tech-
niques for the provided DNA fragments were performed
in a total volume of 25 μl containing 50 ng of genomic
DNA; 0.12 μM of each primer; 100 μM dNTPs; 0.5 units
of AmpliTaq Gold enzyme (Applied Biosystems); 2.5 μl of
GeneAmp 10 × buffer II (10 mmol/L Tris-HCl, pH 8.3, 50
mmol/L KCl), in 2 mmol/L MgCl2 as provided by the
manufacturer. Amplification was performed in a multi-
block system (MBS) thermocycler (ThermoHybaid). PCR
amplification began with denaturation at 95°C for 5 min,
followed by 35 cycles of denaturation at 94°C for 30 s,
annealing at 56°C for 30 s, extension at72°C for 45 s, and
a final extension step at 72°C for 10 min.
DHPLC Analysis
Mutations screening was performed using the Transge-
nomic Wave Nucleic Acid Fragment Analysis System
(Transgenomic Inc.) with a C18 reversed-phase column,
which was based on 2-μm nonporous poly (styrene/divi-
nylbenzene) particles (DNASep column, Transgenomic
Inc.). PCR products were analyzed in a linear acetonitrile
gradient with triethylammonium acetate as the mobile
phase, using buffer A (0.1 M TEAA) and buffer B (0.1 M
TEAA with 25% acetonitrile) (WAVE Optimized, Transge-
nomic Inc.). Heteroduplex analyses were performed
according to the manufacturer's protocol and previous
studies [37,44,45].
Purification of PCR Products
In the mismatch-specific endonuclease process, the
Microcon YM-100 system (Millipore Corp.) was used to
remove excess primers and unincorporated dNTPs to
purify the PCR products.
Mismatch-specific Endonuclease Method
After PCR amplification and purification, the PCR prod-
uct was digested by mismatch-specific endonuclease using
the SURVEYOR kit with the fluorescent capillary electro-
phoresis system (Transgenomic). The PCR products were
assayed in a total volume of 60 μl containing 15 μl of PCR
product, 6 μl of 10 × Surveyor Nuclease reaction buffer, 1
μl of Surveyor Nuclease Enhancer W, and 1 μl of Surveyor
Nuclease W (Surveyor) as provided by the manufacturer.
Mismatch-specific endonuclease digestion was performed
at 42°C for 20 min, followed by adding 6 μl of stop solu-
tion as provided by the manufacturer.
Capillary Electrophoresis
The final mismatch-specific endonuclease digestion prod-
uct (2 μl) was diluted with 10 μl of Hi-Di formamide
(Applied Biosystems) and 0.25 μl of ROX size standard
(Applied Biosystems). Samples were heated at 95°C for 5
min and cooled on ice for 5 min. Each mixture was
injected into the ABI PRISM 310 Genetic Analyzer
(Applied Biosystems) and was separated across a capillary
containing POP-4 polymer (Applied Biosystems). The
results were analyzed using GeneScan application soft-
ware (Applied Biosystems) according to the manufac-
turer's protocol [46].
Sequencing
For sequencing, the PCR products were purified by solid-
phase extraction and bi-directionally sequenced with the
Applied Biosystems Taq DyeDeoxy terminator cycle
sequencing kit (Applied Biosystems) according to the
manufacturer's instructions. Sequencing reactions were
separated on a PE Biosystems 373A/3100 sequencer.
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